Low-grade upper tract urothelial cell cancer (LG-UTUC) is a rare form of cancer that affects the lining of the urinary system, specifically in the renal pelvis or ureter. These cancers can be characterized by their slow growth and lower likelihood of spreading to other parts of the body compared to high-grade tumors. However, LG-UTUC can still be challenging to treat due to its location and the potential for recurrence.
At Urology Specialists of Ohio, Jelmyto®, a recently approved therapy for upper tract urothelial cancer, represents just one of the state-of-the-art options in our comprehensive arsenal against urological cancer
Jelmyto® is an innovative treatment option for LG-UTUC. It is a gel-based formulation of mitomycin, a chemotherapy drug used to treat various cancers. What makes Jelmyto unique is its ability to form a gel at body temperature, allowing it to adhere to the urinary tract lining and deliver the medication directly to the tumor site. This localized delivery system helps maximize the effectiveness of the treatment while minimizing systemic side effects.
Determining if Jelmyto is right for your case depends on several factors. It is primarily indicated for adults with LG-UTUC in the renal pelvis or ureter. Our urologists will consider the size and location of your tumor, your overall health, and previous treatments you may have undergone. Jelmyto is particularly beneficial for patients who wish to preserve their kidneys and avoid radical surgery. While Jelmyto has a well-established safety profile and is proven to help eliminate tumors in patients with LG-UTUC and keep them tumor free, our team will discuss the common side effects and any potential risks associated with the treatment.
The administration of Jelmyto involves a minimally invasive procedure. Typically performed as an outpatient procedure, Jelmyto is typically delivered via a ureteral catheter or nephrostomy tube once a week for six weeks. During each session, the chilled Jelmyto solution gets instilled into the upper urinary tract, where it warms to body temperature and transforms into a gel. Patients are advised to change positions periodically for an hour after instillation to ensure even distribution of the gel throughout the urinary tract.
Jelmyto, a recently approved therapy for upper tract urothelial cancer, represents just one of the state-of-the-art options in our comprehensive arsenal against urological cancers. By staying at the forefront of urological oncology, Urology Specialists of Ohio ensures every patient receives personalized care plans utilizing the latest medical advancements to optimize outcomes and quality of life.
Urology Specialists of Ohio has been an integral part of the community for more than 20 years, and currently serves Springfield, Beavercreek, Xenia, Dayton, and Urbana striving to improve patient care, with excellence in all areas of Urology.
Phone:
(937) 247-6616Fax:
(937) 342-9262Email: